CHU Bordeaux is live on SOPHiA GENETICS

The hospital is using the SOPHiA DDM™ Platform to advance the research of Homologous Recombination Repair Mutated Cancers

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization. The hospital will be using the SOPHiA GENETICS technology to help advance its research on homologous recombination repair (HRR) mutated cancers.

HRR is a DNA repair pathway that acts on DNA double-stranded breaks. Deficiency in HRR (known as HRD) leads to the accumulation of gene mutations and genomic instability, and is a common feature of ovarian, breast, prostate, and pancreatic cancers. HRD can also arise from mutations in a wider set of HRR genes across various cancer types.1, 2, 3 

To detect HRD, researchers often use next-generation sequencing (NGS), which can produce a complex data set that is time-intensive and costly to analyze. The SOPHiA DDM™ Platform uses Artificial Intelligence (AI) and machine learning with patented technologies to analyze and interpret raw NGS data. The Platform also provides a unique approach to molecular cancer testing by combining information from HRR mutations with a measure of genomic scarring. The SOPHiA DDM™ Platform provides reliable and fast HRD results that can help guide the team at CHU Bordeaux in generating data-driven insights.

“Our goal at SOPHiA GENETICS is to help facilitate research and insights for serious conditions such as cancer to enable the widespread adoption of precision medicine as the gold standard of treatment,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “In line with our goal, customers like CHU Bordeaux that are dedicated to research and medical innovation are embracing the foundations for precision medicine by adopting the SOPHiA DDM™ Platform. This will enable the hospital to advance its research on HRR-mutated tumors and be better informed to make data-driven decisions.”

The SOPHiA DDM™ Platform will help CHU Bordeaux create a more efficient bioinformatics workflow for accuracy and simplification where possible when analyzing NGS data. Additionally, with the SOPHiA DDM™ Platform technology CHU Bordeaux will be able to create an in-house database from genomics profiles its researchers analyze. 

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

New Synomics Study Identifies Genomic Pathway to Heavier Eggs

Business Wire

Global Single Cell Genomics Market Report 2022

PR Newswire

Genomic Vision Announces Signing Addendum to Contract with Winance

Business Wire